Options for OpGen

Investors expect that a $17 million series B round will be enough to get genomics play OpGen Inc. to breakeven, according to Evan Jones of jVen Capital.

jVen to a small stake in the company's $23.6 million A round in 2007, and led the new round with participation from other existing investors CHL Medical Partners; Highland Capital Partners; Mason Wells Biomedical; and Versant Ventures...